Evidence map›Paper›PMID 42639299›Full record

ReviewFrontiers in cellular and infection microbiology2026

Molecular mechanisms of antibiotic resistance in Gram-positive and Gram-negative bacteria - a narrative review.

Denisa Claudia Tonco, Cristina Gavrilovici, Ancuta Lupu, Leonard Iosif Pertea, Ileana Ioniuc, Alice Grudnicki, Sorana Caterina Anton, Alin Horatiu Nedelcu, Tania Rusu, Costica Mitrofan and 5 more

Abstract readReview
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Denisa Claudia ToncoGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Cristina GavriloviciGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Ancuta LupuGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Leonard Iosif PerteaGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Ileana IoniucGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Alice GrudnickiGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Sorana Caterina AntonGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Alin Horatiu NedelcuGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Tania RusuRegina Maria Healthcare Campus, Iasi, Romania.
Costica MitrofanGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Manuel Florin RosuGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Ionela Daniela MorariuGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Emil AntonGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Elena Cristina MitrofanClinic of Pulmonary Disease, Iasi, Romania.
Vasile Valeriu LupuGrigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antimicrobial resistance (AMR) represents one of the most pressing global public health challenges of the 21st century, driven by the widespread inappropriate use of antibiotics and the remarkable adaptive capacity of pathogenic bacteria This narrative review provides an integrated comparative analysis of AMR mechanisms across Gram-positive and Gram-negative bacteria, with particular emphasis on clinically significant ESKAPE pathogens. The four principal resistance mechanisms: enzymatic drug inactivation, reduced drug uptake, target site modification, and active efflux, are examined comparatively across both organism groups, with emphasis on how their molecular basis and clinical significance differ between them. Biofilm formation is further addressed as a resistance-amplifying strategy, with discussion of organism-specific differences in matrix composition between Gram-positive and Gram-negative pathogens. Current and emerging diagnostic approaches for AMR detection are reviewed in relation to their differential applicability across organism groups, followed by a discussion of pharmacokinetic/pharmacodynamic optimization as a resistance-prevention strategy. Finally, lariocidin, a structurally novel ribosome-targeting lasso peptide with broad-spectrum activity against both Gram-positive and Gram-negative multidrug-resistant pathogens, is presented as an emerging therapeutic scaffold that circumvents resistance mechanisms operating across both bacterial groups. Where relevant, illustrative examples from pediatric populations are discussed, highlighting how diagnostic challenges and empirical prescribing may compound the impact of resistance in this group. Addressing AMR requires coordinated global efforts that integrate surveillance, research, policy-making, and education to ensure the continued efficacy of antimicrobial treatments.

Indexed as

Anti-Bacterial AgentsDrug Resistance, BacterialGram-Negative BacteriaGram-Positive BacteriaBiofilmsGram-Negative Bacterial InfectionsHumansAnti-Bacterial Agentsantibiotic resistancebiofilmefflux pumpsESKAPE pathogensGram-negative pathogensGram-positive pathogenslariocidin

Identifiers

PMID42639299
PMCPMC13501153

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.